An observational study to follow clinical outcomes for the patients participated in the randomized, phase III trial of sequential capecitabine/5FU plus bevacizumab (Cape/5FU-Bmab) to capecitabine/5FU plus oxaliplatin plus bevacizumab (CapeOX/mFOLOFX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer
Not Applicable
Completed
- Conditions
- Colorectal Cancer
- Registration Number
- JPRN-UMIN000036690
- Lead Sponsor
- Department of Clinical Oncology, Kawasaki MEdical School JSWOG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 311
Inclusion Criteria
Not provided
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of capecitabine/5FU plus bevacizumab in advanced colorectal cancer?
How does the sequential Cape/5FU-Bmab regimen compare to CapeOX/mFOLFOX6-Bmab in terms of progression-free survival and overall survival in metastatic colorectal cancer patients?
Which biomarkers are associated with response to capecitabine/5FU plus oxaliplatin plus bevacizumab in RAS wild-type and mutant colorectal cancer subtypes?
What are the most common adverse events reported in trials combining capecitabine/5FU with bevacizumab or oxaliplatin in advanced colorectal cancer?
How do the outcomes of JPRN-UMIN000036690 compare to trials of regorafenib or trifluridine tipiracil in refractory metastatic colorectal cancer?